2017
DOI: 10.1016/j.ijpharm.2017.02.032
|View full text |Cite
|
Sign up to set email alerts
|

Engineering approaches in siRNA delivery

Abstract: siRNAs are very potent drug molecules, able to silence genes involved in pathologies development. siRNAs have virtually an unlimited therapeutic potential, particularly for the treatment of inflammatory diseases. However, their use in clinical practice is limited because of their unfavorable properties to interact and not to degrade in physiological environments. In particular they are large macromolecules, negatively charged, which undergo rapid degradation by plasmatic enzymes, are subject to fast renal clea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
12
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
5
2
1

Relationship

1
7

Authors

Journals

citations
Cited by 22 publications
(12 citation statements)
references
References 144 publications
0
12
0
Order By: Relevance
“…Preventing cell surface expression of CD83 can significantly inhibit DC-mediated T cell activation [15]. siRNA is considered to be a potent drug molecule that can silence genes associated with pathogenesis, especially in the treatment of inflammatory diseases [48, 49]. The siRNA binds to the RNA-induced silencing complex (RISC); then the passenger siRNA chain departs and initiates the process of RNA interference process, causing mRNA fragmentation and degradation [50, 51].…”
Section: Discussionmentioning
confidence: 99%
“…Preventing cell surface expression of CD83 can significantly inhibit DC-mediated T cell activation [15]. siRNA is considered to be a potent drug molecule that can silence genes associated with pathogenesis, especially in the treatment of inflammatory diseases [48, 49]. The siRNA binds to the RNA-induced silencing complex (RISC); then the passenger siRNA chain departs and initiates the process of RNA interference process, causing mRNA fragmentation and degradation [50, 51].…”
Section: Discussionmentioning
confidence: 99%
“…Treatment with siRNA has a specific inhibitory effect; however, there are problems of in vivo stability and of delivery to locations (Inoue et al 2014;Barba et al 2017). Hsp70 inhibitors such as VER155008 may not obtain the expected inhibiting effects in some cases because of the influence of other chaperones and co-chaperones (Asling et al 2016).…”
Section: Discussionmentioning
confidence: 99%
“…The local transport of siRNA has less obstruction compared to systemic administration. The first of the unique features of the local administration is the need to an easy formulation that requires easier production and application and secondly provides application of lower doses that limit intracellular (time-concentration-dependent) immune responses [14].…”
Section: Physiological Barriers For Sirnamentioning
confidence: 99%
“…In fact, due to collisions with RBCs, microparticles are pushed toward the artery wall where RBCs are virtually absent depending on the shape and size by a radial movement called the "waterfall effect." This event is also called margination, and they have stated that the extravasation cannot occur unless vectors are exposed to margination [14].…”
Section: Physiological Barriers For Sirnamentioning
confidence: 99%